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Primary membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. Discovery of several antibodies has
contributed to an increased understanding of MN. Antibodies against the M-type phospholipase A2 receptor (PLA2R) are present
in 50–100% with primary MN and are associated with a lower frequency of spontaneous remission. High levels are linked with
a higher probability of treatment resistance, higher proteinuria, and impaired renal function, as well as a more rapid decline of
kidney function during follow-up. Immunologic remission precedes reduction of proteinuria by months. Pretransplant evaluation
of PLA2R antibodies is warranted to predict recurrence of disease following renal transplantation. Several risk alleles related to
the PLA2R1 gene and within the HLA loci have been identified, whereas epitope spreading of PLA2R may predict treatment
response. More recently, thrombospondin type 1 domain-containing 7A (THSD7A) antibodies have been discovered in primary
MN. Several other rare antigens have been described, including antibodies against neutral endopeptidase as a cause of antenatal
MN and circulating cationic bovine serum albumin as an antigen with implications in childhood MN. This review focuses on the
progress with a special focus on diagnostic accuracy, predictive value, and treatment implications of the established and proposed
antigens.
1. Introduction
Recent research in the field has unraveled important patho-
genetic insights in the onset of primary membranous
nephropathy (MN). Distinction between primary and sec-
ondary cases (mainly autoimmune disorders, infections,
medications, and malignancy), characterized by a recogniz-
able etiology, is pivotal. A clear difference from a histopatho-
logic perspective is difficult, but absence of phospholipase
A2 receptor (PLA2R) glomerular staining, preponderance of
IgG1-3, and presence of extensive mesangial or subendothe-
lial electron dense deposits may have a value in the diagnosis
of secondary cases [1, 2]. While IgG1 is the predominant IgG
subclass observed in secondary cases (60% of biopsies), IgG4
is predominantly found in subjects with primaryMN (76% of
biopsies) [3]. The exact role of the least represented IgG sub-
class is not completely understood, but it may exhibit distinct
roles compared to IgG1 in allergy and tumor growth [4], and
has attracted considerable interest due to increased incidence
and prevalence of IgG4-related disease [5, 6].
Globally, MN represents the leading cause of nephrotic
syndrome, with a reported annual incidence ranging from
0.2/100.000/year to 1.4/100.000/year and an overall estimate
of 1.2/100.000/year [7]. A male predominance has been
reported in most studies [7, 8], prognosis is related to
renal function decline, and outcome tends to be better
in females [8]. In general, patients present with a greater
degree of proteinuria compared to those with focal segmental
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glomerulosclerosis (FSGS) and minimal change disease
(MCD), but renal survival is assumed to be better compared
to those having FSGS [9–11]. In line with FSGS [12], recur-
rence of disease after kidney transplantation takes place in
approximately 35% of patients [13]. Recurrence is supposed
to occur due to a yet-to-be-defined circulatory factor in
FSGS, while progress in the understanding of MN has led to
identification of circulatory factors leading to disease onset.
While neonatal disease is associated with antibodies against
neutral endopeptidase [14], M-type phospholipase A2 recep-
tor antibody (PLA2R-Ab) [15], and thrombospondin type 1
domain-containing 7A (THSD7A) [16] autoantibodies are
responsible for approximately 80% of primaryMN cases.The
aim of this review is to summarize recent findings in primary
MN, focusing on implications of identified antibodies as well
as their diagnostic accuracy and therapeutic impact.
2. M-Type Phospholipase A2 Receptor
Autoantibodies and Glomerular
Phospholipase A2 Receptor in Primary
Membranous Nephropathy
PLA2R-Abswere first identified byWestern-blotting and sub-
sequentmass spectrometry in 26 out of 37 (70%) patientswith
primary MN. The 185-kD protein was absent in secondary
MN as well as other proteinuric diseases (diabetic kidney
disease, FSGS, or other autoimmune disorders). Moreover,
samples reacting with the glycoprotein recognized recombi-
nant PLA2R in vitro and PLA2R could be detected in human
glomeruli. Glomerular deposits of patients with primary
MN had a predominance of IgG4-subclass antibodies, and
PLA2R colocalizedwith IgG4 in glomeruli [15]. A subsequent
large multicenter study from Europe including 117 patients
revealed presence of PLA2R-Ab in 74% and 72% using an
immunofluorescence test (IFT) or ELISA, which increased to
76% when positivity in either test was considered as positive
finding. The IgG4 subclass was present in 69% of all patients
and correlated best with antibody positivity measured by IFT
or ELISA [17]. Analysis of PLA2R staining in MN revealed
positivity in 69% of 88 patients and was accompanied by
PLA2R-Ab positivity in 60/61 patients (different time points
of blood sampling). Enhanced PLA2R staining was exclu-
sively found in primary MN and, of note, IgG4 staining was
present in 95% of primary MN and in only 20% with sec-
ondary causes [18]. A study from theNetherlands investigated
18 samples during active disease and found a frequency of
77.8% PLA2R-related MN in their cohort [19]. In a prospec-
tive study by Hoxha and colleagues, PLA2R-Ab were mea-
sured in treatment-naı¨ve patients. PLA2R-Ab were detected
in 133/163 (81.6%) patients [20].
Several studies from Asia investigated presence of
PLA2R-Ab and glomerular PLA2R staining. In a Korean
study, 69/100 patients (69%) had detectable PLA2R-Ab as
assessed by Western blot [21]. PLA2-related MN as detected
either by IFT, by ELISA, or by glomerular PLA2R stainingwas
reported in 94/114 (82.5%) in a study from India [22]. A study
fromChina including consecutive patients with primaryMN
reported a frequency of 64.6% (53/82) [23]. In contrast to
this low frequency of antibody positivity, another study from
China found PLA2R-Ab in 49/60 patients (81.7%). When
decreasing the dilution of samples for Western blot analysis,
10 of the remaining samples had low titers, albeit with a
weaker strength compared to the other positive samples
[24]. A larger study including 572 patients found detectable
PLA2R-Ab in 68.5% (𝑛 = 392) as assessed by ELISA. Among
the antibody negative cases (𝑛 = 180), glomerular staining
was present in 70.6% (𝑛 = 127) [25]. Similar high frequency
of PLA2R-MN (92.2%) was reported from another Chinese
study analyzing 179 primary MN patients [26]. In Japanese
patients, the prevalence of PLA2R-Abmaybe lower compared
to the rest of the world. A retrospective analysis of patients
with 100 primary MN cases (after screening for clinical or
laboratory signs of a secondary cause) revealed positivity
in 53% of patients, with a higher prevalence observed in
these subjects with nephrotic range proteinuria (61% versus
43%) [27]. Another study found PLA2R-Ab in 50% of their
patients, whereas similar frequency of positive glomerular
PLA2R staining could be detected in two cohorts (52.6 and
52.7%, resp.) [28, 29]. The respective studies reporting adult-
onset primary MN are summarized in Table 1.
Analysis of PLA2R-Ab screening during remission
showed a limited predictive value to identify PLA2R-related
MN, with 8 out of 37 (22%) samples testing positive, whereas
PLA2R was found in 22 of 37 (59%) corresponding biopsies
[43]. PLA2R-Ab levels have been examined in childhoodMN
and were present to a lesser extent in a pediatric population,
ranging from 2/34 (5.9%) to 10/22 (45.5%) patients reported
from Japan and Northern America [44, 45]. In contrast,
Kumar and coworkers reported PLA2-related MN in 15/18
(83.3%) of adolescents with primary MN [46].
In general, discrimination between primary and sec-
ondary cases is pivotal. In individual studies, a substan-
tial heterogeneity has been reported. To better characterize
PLA2R-Ab as a marker for primary MN, two meta-analyses
were conducted.Themore recent study byDai and colleagues
included 19 studies with 1160 patients. PLA2R-Ab positivity
yielded a sensitivity of 0.68, a specificity of 0.97, a diagnostic
odds ratio of 73.75, and an area under the curve of 0.82 when
comparing primary and secondaryMN.The respective values
for glomerular PLA2R staining were 0.78, 0.91, 34.70, and
0.84 for the same parameters without heterogeneity [47].
The GEMRITUX trial comparing nonimmunosuppres-
sive antiproteinuric treatment (NIAT) with rituximab against
NIAT alone found PLA2R-Ab in three subjects who were
initially found to be negative [38]. In line, “seroconversion”
has been reported in a recent case series and a “kidney in the
sink”-hypothesis has been generated, discussing the role of a
PLA2R-Ab buffer capacity exhaustion of the kidney leading
to antibody detection at a later stage [48]. In contrast to this
assumption, a case report reported presence of PLA2R-Ab in
a patient eight months ahead ofMN presentation. PLA2R-Ab
was measured during a thrombophilia work-up [49].
Taken together, the ideal time point of sample collection
is at the time of kidney biopsy and ahead of treatment
initiation, whichmay account formisclassification as PLA2R-
Ab negative MN in some cases. Detection of serum PLA2R-
Ab by diverse commercial measures is reliable, but cases of
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Table 1: A summary of studies investigating the prevalence of either phospholipase A2 receptor antibodies, glomerular phospholipase
A2 receptor staining, or both in primary membranous nephropathy. ELISA (Enzyme-Linked Immunosorbent Assay), IFT (Indirect
Immunofluorescence Test), PLA2R (phospholipase a2 receptor), PLA2R-Ab (phospholipase a2 receptor antibody), WB (Western blot).
∗Dilution of serum samples was decreased to 1 : 10, and exposure time was increased to 10 minutes.
Reference Country Prevalence(PLA2R-Ab) Detection method
Prevalence (PLA2R
staining) Predominant IgG subclass
[15] USA 26/37 (70%) WB
[17] Netherlands, France, UK 87/117 (74%),84/117 (72%)
IFT,
ELISA IgG4 (81/87, serum)
[18] Germany 60/88 (68%) IFT 61/88 (69%) IgG4 (58/61, biopsy)
[19] Netherlands 14/18 (78%) WB IgG4 (14/14, serum)
[20] Germany 133/163 (82%) IFT, ELISA
[21] Korea 69/100 (69%) WB
[22] India 75/114 (65%),76/114 (67%)
IFT,
ELISA 86/114 (75%)
[23] China 53/82 (65%)51/82 (62%)
IFT,
ELISA
[24] China 49/60 (82%)59/60 (98%)∗ WB
[25] China 392/572 (69%) ELISA 514/572 (90%)
IgG4 (97.7% (PLA2R-Ab/R
+/+), 98.4% (PLA2R-Ab/R
−/+))
[26] China 165/179 (92%) IgG4 (167/179, 93%)
[27] Japan 53/100 (53%) WB
[28] Japan 19/38 (50%)19/38 (50%)
IFT,
ELISA 20/38 (53%) IgG4 (20/20, biopsy)
[29] Japan 29/55 (53%) IgG4 (28/29, biopsy)
PLA2R-related MN may be missed by antibody detection
only. Thus, staining for PLA2R antigen in the kidney should
be considered to overcome this limitation. A preponderance
of IgG4 is found in cases with PLA2R-related MN in serum
and kidney specimens. Presence of PLA2R-Ab show a lower
prevalence in Japan (around 50%) and in early-onset MN
compared to other investigated cohorts (PLA2R-Ab positivity
ranging from 65 to almost 100%).While PLA2R-Ab detection
and predominant IgG4 presence may be considered a good
measure to discriminate primary from secondary causes of
MN inCaucasians, this is of lower validity in Chinese patients
as shown by the recent meta-analyses.
2.1. Secondary Membranous Nephropathy and PLA2R Ab
or PLA2R Staining Positivity. Initial studies have reported
PLA2R-Abpositivity occurring in primaryMNonly.With the
increasing body of evidence, secondary MN forms positive
for either PLA2R-Ab or glomerular PLA2R staining have
been identified.
In a cohort of patients with membranous lupus nephritis
(LN), PLA2R-Abs were undetectable [30]. This is in line with
Japanese studies reporting PLA2R-Abpositivity exclusively in
patients with primary MN [27] or absence of either PLA2R-
Ab or glomerular staining for PLA2R [28], whereas a low
frequency (5.4%) could be observed in another analysis (one
case HBV-associated and one malignancy-related) [29]. Pos-
itive PLA2R staining had a sensitivity of 75% and a specificity
of 83% for primary MN in a large US study (85 primary
and 80 secondary cases). Predominant secondary causes were
hepatitis C (7/11, 64%), sarcoidosis (3/4, 75%), and malig-
nancy (3/12, 25%), whereas positive staining was found to a
lesser extent in patients with autoimmune diseases (1/46, 2%).
Interestingly, all PLA2R positive secondaryMN cases showed
IgG4-predominant staining [31]. A French nationwide sur-
vey retrospectively analyzed kidney biopsies from patients
with sarcoidosis and found PLA2R antigen in immune
deposits in all patients. Serial serum samples were obtained
in two patients and circulating PLA2R-Ab levels were in
accordancewith sarcoidosis activity and both, PLA2R-Ab and
PLA2R,were predominantly related to the IgG4 subclass [50].
In a Chinese study, 84% of 102 tissue samples of patients
with primary MN were PLA2R positive. Among secondary
causes, one out of 38 patients with class V LN and 64%
with hepatitis B virus-associated MN (HBV-MN) showed
positive PLA2R staining [32]. Of 22 cases with secondary
MN (HBV-MN, LN or both), 36.4% (8/22) had detectable
PLA2R-Ab [23]. Analysis of 24 patients with psoriasis and
MN revealed PLA2R-Ab and PLA2R positivity in 7 (29.2%)
subjects. Among the patients with PLA2R-positivity, a major-
ity showed IgG4 predominance on immunofluorescence
(IF) [33]. Secondary causes of MN were accompanied by
detectable PLA2R-Ab in a minority of patients in a Chinese
study, including 1/20 positive cases with LN, 1/16 with
HBV-MN, and 3/10 with malignancy-associated MN. In line
with other observations, IgG4 was the predominant PLA2R-
reactive subclass [24]. A Korean study found PLA2R-Ab in
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Table 2: Secondary causes of membranous nephropathy and the prevalence of either PLA2R-Ab or positive glomerular PLA2R staining are
summarized. AID (autoimmune diseases), ELISA (Enzyme-Linked Immunosorbent Assay), IgG4-RD (IgG4-related disease), IFT (Indirect
Immunofluorescence Test), LN (lupus nephritis), PLA2R (Phospholipase A2 Receptor), PLA2R-Ab (phospholipase A2 receptor antibody),
and WB (Western blot). ∗Notably, 25/39 (64%) of patients with hepatitis B-associated MN had detectable PLA2R staining, whereas PLA2R
positivity was found in 1/38 (2.6%) of lupus nephritis cases. ∗1By decreasing the dilution, 2 additional cases of hepatitis B-associatedMNwere
considered positive.
Reference Country Prevalence(PLA2R-Ab)
Detection
method
Prevalence (PLA2R
staining)
Predominant IgG
subclass Entities
[15] USA 0/8 (0%) WB LN, hepatitis B
[30] Sweden 0/25 (0%) IFT LN
[27] Japan 0/31 (0%) WB AID, cancer, drugs, hepatitis B,others
[28] Japan 0/21 (0%) IFT, ELISA LN, cancer, hepatitis B
[29] Japan 2/37 (5%) IgG4 (2/2, biopsy) AID, cancer, drugs, hepatitis B,hepatitis C, thyroiditis
[31] USA 14/80 (18%) IgG4 (6/6, biopsy) AID, cancer, hepatitis B, hepatitis C,HIV, syphilis
[32] China 26/77 (34%)∗ LN, hepatitis B
[23] China 8/22 (36%) IFT, ELISA LN, hepatitis B
[33] China 7/24 (29%) IFT 7/24 (29%) IgG4 (5/6, biopsy) psoriasis
[24] China 5/46 (11%)7/46 (15%)∗1 WB IgG4 LN, cancer, hepatitis B
[21] Korea 2/9 (22%) WB LN, cancer, hepatitis B, hepatitis C
[26] China 2/69 (3%) IgG4 (2/2, biopsy) LN, cancer, hepatitis B, IgG4-RD
two out of nine patients with secondary MN (1 HBV and 1
malignancy-associated) and both showed predominant IgG4
immunostaining [21]. Positive PLA2R-staining was found in
2/26 (7.7%) of patients with HBV-MN and 2/2 (100%) pre-
senting with malignancy. All patients with secondary causes
and detectable glomerular PLA2R staining had predominant
IgG4deposition [26].The respective findings are summarized
in Table 2.
A preponderance of IgG4 staining on IF is assumed to
be present in primary MN. As discussed by De Vriese and
colleagues, the question arises whether some of these cases
represent true secondary MN or rather PLA2R-related MN
with coincident secondary diseases [51]. A higher frequency
of secondary causes associated with PLA2R-Ab or PLA2R
staining has been reported inChinese studies, especially cases
with hepatitis B-associated MN known to be endemic in
China. Among the diseases with antibody positivity or pos-
itive staining, hepatitis B- or C-associated MN, malignancy-
associatedMN, and sarcoidosis emerged to be predominantly
found.
2.2. Correlation of PLA2R-Ab Titers with Clinical Characteris-
tics. In a study including 101 primary MN patients, baseline
creatinine levels appeared to be higher in PLA2R-Ab positive
patients, whereas baseline rate of proteinuria correlated with
PLA2R-Ab levels. Spontaneous remission was recorded more
often in patients being PLA2R-Ab negative [34]. Analysis of
a Dutch cohort (𝑛 = 77) revealed a correlation of PLA2R-
Ab titers with baseline proteinuria, serum creatinine, and
baseline estimated glomerular filtration rate (eGFR) after
adjustment for fractional IgG excretion (as representative of
urinary loss of antibodies). Dividing patients into tertiles
based on ELISA titers, renal failure tended to occur more
frequently in patients belonging to the group in the highest
tertile (PLA2R-Ab titer > 610U/ml) and these patients had
a significantly lower incidence of spontaneous remission
compared to the lowest (PLA2R-Ab titer 41–175U/ml) tertile
(4 versus 38%, resp.). Accordingly, physicians were prompted
to initiate immunosuppression more often in patients in the
highest tertile compared to both other groups, whereas time
to treatment response was significantly shorter in patients
within the lowest tertile [17]. A single-center study from
the same institution including 18 primary MN cases high-
lighted correlation of PLA2R-Ab with proteinuria, serum ß2-
microglobulin (ß2m), urinary IgG excretion, urinary ß2m,
and serum creatinine, whereas eGFR was negatively corre-
lated [19]. Another large study including 118 PLA2R-Ab pos-
itive patients established different tertile values, with tertile 1
ranging from 20 to 86U/ml, tertile 2 from 87 to 201U/ml,
and tertile 3 > 202U/ml. Patients in tertile 3 were older,
had a higher baseline systolic blood pressure, and tended
to have more severe proteinuria. The proportion of patients
reaching the predefined primary end point, namely, serum
creatinine increase ≥ 25% and a creatinine value ≥ 1.3mg/dl,
was significantly higher in tertile 3 compared to tertile 1 (69%
versus 25%). At the end of follow-up, proteinuria and PLA2R-
Ab levels were higher in patients belonging to tertile 3 [35]. In
a cross-sectional analysis, risk of progressive kidney function
decline over a long observation period (up to 5 years) was
increased in patients with higher PLA2R-Ab levels (high titer
> 88 𝜇/ml versus low titer< 24 𝜇/ml) [36]. In theGEMRITUX
study, a titer of < 275U/ml was significantly associated
with achieving the primary end point (complete or partial
remission) [38]. A clear association between proteinuria
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and serum PLA2R-Ab levels and serum creatinine could
be confirmed by a prospective study including 133 patients
with detectable antibodies. PLA2R-Ab titers at baseline were
significantly higher in those patients who did not experience
remission during follow-up. Patients having lower PLA2R-
Ab levels reached remission significantly faster compared
to those with higher titers at baseline [20]. Another study
from India observed a significantly higher proportion of
complete remissions in the combined lower and intermediate
range PLA2R-Ab tertile compared to those belonging to the
highest tertile. Furthermore, resistant diseasewas common in
patients with a baseline titer > 300 RU/ml (55.2%), whereas
remission was frequently observed in those with a titer of <
100 RU/ml at baseline (68.2%). In general, detectable PLA2R-
Abs were associated with treatment resistance compared to
patients with no antibodies [22]. In a large study from China,
detectable PLA2R-Abs (𝑛 = 392) were associated with a
higher level of proteinuria and a lower level of eGFR. A
weak correlation of antibody levels with proteinuria, serum
albumin, and eGFR was shown. Moreover, patients with a
positive PLA2R-Ab test and glomerular PLA2R staining were
more likely not to achieve remission compared to those with
undetectable antibodies and positive glomerular staining.
In general, patients with a higher PLA2R-Ab or glomerular
PLA2R rate had a higher proportion of failure to achieve
remission. Combined positivity was a significant predictive
value for no remission [25]. In line with several other reports,
PLA2R-Ab positivity in Korean patients was associated with
more severe proteinuria and lower serum albumin [21].
Proteinuria and number of patients having nephrotic range
proteinuria were significantly higher in PLA2R-Ab positive
cases in a Chinese study [23]. In a Japanese analysis including
19 patients with and without detectable PLA2R-Ab in each
group, serum IgG was significantly lower in patients with
antibodies, whereas proteinuria tended to be higher [28].
Respective associations/correlations have been highlighted in
Table 3.
Taken together, based on the available data it is not
possible to provide definite PLA2R-Ab cut-off, since different
values have been reported in the respective studies. Neverthe-
less, in several studies, patients within the highest tertile had
worse renal outcome and more frequently treatment resis-
tance towards initiated immunosuppression. Notably, two
reports have used purified protein to coat ELISA plates [17,
36], whereas the remainder used a commercially available kit
[22, 35, 38]. High PLA2R-Ab titers (exceeding 250–300 IU/L)
have been associated with more severe proteinuria, higher
serum creatinine/lower eGFR, serum/urinary ß2M, and uri-
nary IgG excretion.
2.3. PLA2R-Ab Presence and Decline Predict Treatment
Response. PLA2R-Abs were present during clinical disease
activity, whereas a decline or complete disappearance of
PLA2R-Ab preceded resolution of proteinuria [15]. In a first
multicenter retrospective study, the effects of rituximab on
PLA2R-Ab levels were tested. 25 of 35 (71%) patients had
detectable PLA2R-Ab and these antibodies disappeared or
declined in 17 (68%) patients within 12 months following rit-
uximab treatment, accompanied by a higher rate of complete
or partial remission compared to those with a persistent
antibody titer (59% and 88% versus 0% and 33% after 12 and
24 months). Changes in antibody titers preceded changes in
proteinuria [40].
An observational study assigning patients either to oral
cyclophosphamide or to mycophenolate mofetil and corti-
costeroids for 12 months evaluated PLA2R-Ab (𝑛 = 34/48)
in retrospective. By 2 months of treatment, PLA2R-Ab levels
declined from 428U/ml to 24U/ml. Antibody status at the
end of treatment predicted 5-year outcome, with 58% (14/24)
of patients with absent PLA2R-Ab achieving persistent remis-
sion compared to 0 out of 9 in thosewith persisting antibodies
[41]. Combined treatment with rituximab and cyclosporine
for 6 months of revealed PLA2R-Ab negativity in 77.8% after
3 months and in all at least once during follow-up, which
was accompanied by remission. In two patients with relapse,
reemergence of PLA2R-Abwas associatedwith re-occurrence
of proteinuria [52]. A recent randomized controlled trial
comparing NIAT and rituximab against NIAT alone found
significantly more PLA2R-Ab negativity and decreasing titers
in the NIAT-rituximab group. In the group with immuno-
logic remission, the primary end point (complete or partial
remission after 6 months) was achieved in 43% compared to
18% with persistent antibody positivity [38]. In 81 antibody-
positive patients receiving a B-cell driven (375mg/m2 once
and a second infusion when more than five circulating B-
cells/mm2 were detected after one week) or a fixed regimen
(375mg/m2 four times, one week apart), a lower PLA2R-
Ab titer and full depletion after six months significantly
predicted remission. In general, antibody decline preceded
proteinuria and, particularly, a 50% reduction of PLA2R-
Ab preceded equivalent proteinuria reduction by 10 months.
Reappearance of PLA2R-Ab predicted disease relapse [37]. A
similar pattern of PLA2R-Ab course was found in a Dutch
study, showing a significant decline in the remission phase
and a reappearance of PLA2R-Ab during relapse [19]. In a
prospectiveGerman study, a decrease in PLA2R-Ab levelswas
accompanied by a steady increase in serum albumin. After
threemonths of follow-up, a 45%decrease of PLA2R-Ab titers
was paralleled by a 25% decrease in proteinuria in a cohort
of 133 patients. The changes were even more pronounced
in patients receiving immunosuppression, with a decline in
PLA2R-Ab levels ranging from 69 to 81% and proteinuria
by 38.8% [20]. In another analysis from India including 114
patients, a decline over 90% in PLA2R-Ab decline in PLA2R-
Ab titers by 12 months was accompanied by remission in
85.4%, whereas a decline lower than 50% in the same period
was associated with persistent nephrotic range proteinuria in
87.5%. A correlation between proteinuria and serum albumin
with PLA2R-Ab titers at 6 and 12 months was found [22]. In a
recent Chinese study comparing PLA2R-relatedMN (𝑛 = 91)
with negative patients (𝑛 = 13), the total remission rate
was significantly higher in patients with absent PLA2R-Ag
staining [39].
A subanalysis of the prospective study conducted by
Hoxha and colleagues analyzed the clinical outcome of
included patients with nonnephrotic range proteinuria. Dur-
ing the follow-up period, significantly more patients with
detectable PLA2R-Ab developed nephrotic range proteinuria
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(13 out of 16 patients) compared to those that tested negative
(five out of 17). In accordance with this finding, immunosup-
pression was initiated more often in patients with PLA2R-
Ab (13 versus 2 patients, resp.). At the end of follow-up,
persistence of PLA2R-Ab was associated with no remission
of proteinuria and a decline in renal function [42]. Findings
have been highlighted in Table 4.
Taken together, higher baseline PLA2R-Ab titers are
associated with worse renal outcome and resistance towards
immunosuppressive therapy. In general, decline in anti-
body levels precede changes in proteinuria by months, irre-
spective of the immunosuppressive measure. Moreover, re-
appearance of PLA2R-Ab is a strong predictor of disease
relapse.
2.4. Recurrence of Disease after Transplantation and PLA2R-
Ab. In a study by Quintana and colleagues, recurrence
was observed in 7 of 21 (33.3%) patients. PLA2R-Abs were
measured ahead of kidney transplantation and were positive
in 85.7% and 35.7% of the recipients with and without recur-
rence, respectively. A correlation of PLA2R-Ab positivity at
the time of graft biopsy and before transplantation with
recurrence of primary MN was found by the authors. A
PLA2R-Ab cut-off level of 45U/ml could predict recurrence,
with a sensitivity of 85.3% and a specificity of 85.1%. Presence
of HLA-DQA1 05:01(05) and HLA-DQB1 02:01 was reported
in 6 of 7 patients with recurrent MN and was associated
with the highest pretransplantation PLA2R-Ab levels [53].
These findings were in part corroborated by another single-
center study. Among the six patients (37.5%) with recur-
rence, a positive ELISA with a titer > 30 RU/ml provided
a sensitivity and specificity of 83% and 100%, respectively.
The risk alleles were found in 5 out of six patients (83%).
Combination of both above-mentioned studies (𝑛 = 37)
yielded a sensitivity of 85% and a specificity of 92% to predict
recurrence with a PLA2R-Ab titer of > 29U/ml [54]. Another
study including 10 patients with primary MN reported an
association of persistent IgG4 PLA2R-Ab and the respective
antibody titer after six months with the recurrence of disease
[55]. Moreover, persistence or reappearance of PLA2R-Ab
after kidney transplantation was associated with increasing
proteinuria and treatment-resistant recurrent MN in another
case series [56]. Taken together, a PLA2R-Ab titer before
renal transplantation > 30 or > 45U/ml (depending on the
respective publications), persistence, or reappearance during
follow-up may predict recurrence of disease. This needs
to be confirmed by further studies assessing patients in a
prospective manner.
2.5. Immunodominant Epitope Region and Impact of Epitope
Spreading on Outcome. Epitopes were identified by SPOT
(peptide arrays on membrane) technology and detected
by Western blot. Restricting analysis to the IgG4 subclass
yielded lower background and stronger signals localized to
seven consensus epitopes, which were in the extracellular
domain of the PLA2R. Six of them were localized to the
C-type lectin-like domains (CTLDs, one in CTLD1, one in
CTLD2, two in CTLD6, and two in CTLD8), whereas one
was located to the N-terminal cysteine-rich region (C-R)
[57]. Further research aimed at deciphering the responsible
epitope responsible for PLA2R-Ab binding. Fresquet et al.
identified themajor epitopewithin theN-terminus toCTLD3
(comprising a complex of CysR, FnII, and CTLD1–CTLD
3) of PLA2R which was recognized by 90% of human
PLA2R-Ab and effectively competed for the bindingwith full-
length PLA2R. Further experiments usingmass spectrometry
revealed a pivotal role of peptide 1 and peptide 2, representing
the ß1 and ß3 strain from the ricin domain. Extension of
peptide 1 towards peptide 2 is exerted by a 31-mer within
the cysteine-rich (CysR) region, and competitive binding
analyses revealed the essential role of 31-mer in the binding
of PLA2R-Ab [58]. In line with the results described above,
Kao and colleagues reported recognition of patient sera by a
protein complex consisting of the CysR, fibronectin-like type
II (FnII), and CTLD1 domains of PLA2R. Binding analysis
comparing full-length PLA2R and the complex of CysR-FnII-
CTLD1 indicated an equally efficacy in the recognition of
PLA2R-Ab positive patient sera [59]. Since 10%of patients did
not show binding to the described epitopes, it was assumed
that a further epitope in themoreC-terminal regionmay exist
[60]. Further in depth analyses led to the identification of
the three pivotal epitopes responsible for PLA2R-Ab binding.
Seitz-Polski et al. described the loss of recognition in all
tested patients (𝑛 = 50) after the deletion of the three
epitopes, namely CysR, CTLD1 and CTLD7. Based on their
findings, they set up ELISAs to specifically measure presence
of antibodies directed against these domains. A total of 69
patients with presence of PLA2R were tested, and CysR as
the dominant and most common epitope was recognized
in 68 patients, whereas the CTLD1 and CTLD7 domains
were recognized in 42 and 32 sera, respectively. Based on
these findings, they classified patients according to antibody
presence into a CysR (CysR antibodies only, 𝑛 = 23), CysRC1
(CysR and CTLD1 only, 𝑛 = 14) and a CysRC1C7 group (with
presence of antibodies against all domains, 𝑛 = 32).TheCysR
antibodies were significantly higher in the latter two groups
compared to the CysR group. Patients in the CysR group
were significantly younger and their baseline proteinuria was
lower compared to the other two groups, while a proteinuria
over 5 g/g creatinine was most frequently found in the
CysRC1C7 group. Furthermore, a progressive increase of
proteinuria was accompanied by a progressive increase in
CTLD7. Assessment of outcome revealed significantly more
spontaneous remissions in the CysR group, whereas the
occurrence of end stage renal increase was limited to the
CysRC1 and CysRC1C7 groups and proteinuria increased
from CysR to CysRC1C7. In accordance, the proportion of
patients with a 30% increase in serum creatinine was higher
in the CysRC1 and CysRC1C7 groups. Multivariate analysis
retained CysRC1, CysRC1C7 and high titers of PLA2R-Ab
as independent risk factors for poor renal prognosis. Serial
samples were available for a subset of patients and an epitope
switch was observed in a minority, associated with a change
in clinical presentation (i.e., one patients switched from
the CysRC1C7 to the CysR group and entered remission
following initiation of immunosuppression). ELISA tests
were set up for the detection of IgG4 antibodies only. Analysis
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of other subclasses highlighted that anti-CTLD7 antibodies
were exclusively restricted to the IgG4 subclass [61].
The identification of the immunodominant epitope
regions of PLA2R have further provided insight into patho-
genesis. Moreover, the CysRC1, CysRC1C7 and higher titers
of circulating PLA2R-Ab may be considered as independent
risk factors for poor prognosis. Moreover, epitope spreading
has been observed, indicating changes in both directions
(high risk phenotype to the CysR group and vice versa).
It is tempting to speculate that specific developments (i.e.,
commercially available ELISA kits) will further help to
facilitate identification of patients bearing a high risk of
treatment resistance or progressing to end stage renal failure.
2.6. Identification of Susceptible Loci Associated with Pri-
mary Membranous Nephropathy. A genome-wide associa-
tion study (GWAS) was employed to identify risk alleles
responsible for the onset of primary MN. Three cohorts
(with Dutch, French and British patients) were analyzed and
independently displayed a significant association with HLA-
DQA1 on chromosome 6p21. In a joint analysis, compris-
ing 556 patients with primary MN and 2338 controls, the
authors identified the most significant association within
HLA-DQA1 and PLA2R1 on chromosome 2q24 [62]. A
subsequent study from Spain including 89 primary MN
patients and 286 controls confirmed genetic associations
with HLA-DQA1 and PLA2R1. Interestingly, combination of
the susceptibility genotypes (A/A and A/G for HLA-DQA1
and A/A for PLA2R1) significantly predicted response to
treatment, which became even more apparent after adjust-
ment for baseline proteinuria. Moreover, carriers of the
A/A or A/G genotype for HLA-DQA1 had a longer mean
doubling of serum creatinine-free survival [63]. A study from
Germany observed an association between classical HLA
alleles (DRB1∗0301-DQA1∗0501-DQB∗0201 haplotype) and
primary MN. Whereas PLA2R1 was exclusively identified in
primary MN, the HLA-DQA1 risk allele was associated with
LN, diabetic nephropathy and FSGS as well [64]. In a cross-
sectional study from the UK, HLA-DQA1∗05:01 and HLA-
DQB1∗02.01 were associated with higher PLA2R-Ab levels
[36]. In a large monocentric study, analysis of the risk alleles
revealed that homozygous carriage of the PLA2R1Aallele was
associated with a 2-fold higher PLA2R-Ab level compared to
A/G and G/G carriers [37].
Similar results were reported in non-Caucasian patients
with primaryMN.A study from India compared 114 cases and
95 healthy controls and observed differences in the PLA2R1
and HLA-DQA1 SNPs which became more evident when
studying PLA2R-related cases only [22]. In a large North-
ern American analysis, PLA2R1 SNPs were associated with
PLA2R-related MN in Caucasians only. A strong epistasis
between PLA2R1 and HLA-DQA1 was found [65]. In African
Americans, 120 PLA2R-related MN biopsies were screened
for the presence of APOL1 risk alleles, identifying 46 cases
with 0, 51 cases with 1 and 23 cases with 2 APOL1 risk alleles.
Presence of two risk alleles was associated with histologic
features implicated in worse renal outcome [66].
Analysis of 1112 Chinese patients and 1020 healthy con-
trols revealed a strong association between three SNPs within
PLA2R1 and one SNP within HLA-DQA1 and a potentiation
when risk alleles were combined [67]. Restricting analysis
to the MHC region in PLA2R-positive primary MN, HLA-
DRB1∗15:01 and HLA-DRB3∗02:02 were strongly associated.
WhereasHLA-DRB3∗02:02 was found in a comparable num-
ber of PLA2R-negative MN, HLA-DRB1∗15:01 was found in
81.8% of patients with PLA2R-related MN compared to 16%
of PLA2R-negative MN and 21% of the healthy controls. A
replication cohort confirmed the findings of both HLA loci.
Interestingly, in a joint analysis, 387 patients (98.7%) carried
at least one of the proposed HLA risk alleles [68]. Another
Chinese study included 261 cases and 599 healthy controls.
HLA-DRB1∗15:01 and HLA-DRB1∗03:01 were independently
associated with primary MN. PLA2R-Ab positivity was asso-
ciated with the carriage of one of the risk alleles, whereas
association remained at a lower degree forDRB1∗15:01, while
DRB1∗03:01 lost its effect [69]. In a Japanese cohort compris-
ing 183 patients with primary MN and 811 healthy controls,
several tested PLA2R1 SNPs were associated. Moreover, the
association of HLA-DRB1∗15:01 could also be observed,
whereasHLA-DQB1∗06:02 emerged as a second independent
risk allele [70]. To identify rare genetic variants in PLA2R1, all
30 exons of PLA2R1 were sequenced. Although the general
association between PLA2R1 and primary MN could be
confirmed, no evidence was provided that rare variants
within the coding region cause the proposed association
between primary MN and the PLA2R1 gene [71].
Despite progress in the understanding of genetics related
to primaryMN, there is a lack of heritability. One report from
1984 highlighted occurrence ofMN in three pairs of brothers,
with one pair being monozygotic (HLA-identical) twins [72].
In general, the presence of HLA-DQA1 and PLA2R1 risk
alleles confers a significant association with primaryMN and
the combination of risk phenotypes potentiates the risk to
develop MN in most ethnicities. Particularly, MHC class II
molecules play a pivotal role in MN. In Chinese patients
with primary MN, carriage of HLA-DRB1∗15:01 confers a
significant risk to develop PLA2R-relatedMN, whereasHLA-
DRB1∗03:01 or HLA-DRB∗06:02 may carry a risk to develop
either PLA2R-related or unrelated MN.
3. Thrombospondin Type 1
Domain-Containing 7A in (Primary)
Membranous Nephropathy
Since about 20–30% of cases with primary MN may exhibit
other antigens, a similar approach as with the discovery of
PLA2R-Ab was chosen to identify further antigens. Throm-
bospondin type 1 domain-containing 7A (THSD7A) was
identified by Western-blotting and subsequent mass spec-
trometry and has a molecular size of approximately 250 kDa.
Among patients with PLA2R-Ab negative primary MN,
THSD7A was found in 6 out of 44 patients in a European
and in 9 out of 110 patients in a US cohort. In accordance
with PLA2R-Ab, IgG4 was the predominant IgG subclass
of anti-THSD7A, and colocalization of IgG4 and THSD7A
was observed in renal tissue specimens. Staining for nephrin
colocalized with staining for THSD7A, suggesting expression
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of THSD7A in proximity to the podocyte foot processes.
Interestingly, anti-THSD7A antibodies were more frequently
observed in women (65% versus 27%) [16]. A single-center
study from Japan including consecutive patients with MN
found THSD7A-related MN in five out of 55 patients (9.1%).
Again, total numbers were low, but the authors found
that patients with THSD7A-related MN were significantly
younger compared to PLA2R-related MN and a female
predominance (three out of five), which was in contrast to
patients being PLA2R-positive [29]. Lower prevalence was
reported in a Chinese cohort (three patients with primary
MN), and additionally two patients had secondary causes
(one tumor-associated and one hepatitis B-associated, overall
3.7%). Importantly, IgG4 staining was positive in primary
and secondary causes [73]. Analysis of consecutive biopsies
from the Boston cohort revealed a positive staining for
THSD7A in 7/258 (3%) patients, whereas two cases pre-
sented with dual (PLA2R and THSD7A) positivity (1%) [74].
Concomitant occurrence of THSD7A-relatedMN andmixed
adenoneuroendocrine carcinoma of the gallbladder with
positive staining in the kidney, the gallbladder and an affected
lymph node highlighted a potential link between THSD7A-
positivity and malignancy. Screening of 1009 patients with
MN revealed further 25 patients with positive anti-THSD7A
antibodies. Of these, seven had a malignancy [75]. Further
analysis of consecutive MN patients revealed a prevalence of
2.6% out of 345 patients, with a majority being female. The
association between THSD7A-related MN and malignant
disease exceeded the number of PLA2R-related MN and
malignancy. After inclusion of the retrospective cohorts and
analysis of samples derived from 1276MNpatients, 8 out of 40
patients with detectable anti-THSD7A antibodies presented
with malignancy and the median time from diagnosis of MN
and development or detection of malignancy was 3 months.
Again, a female predominance was reported by the authors.
Achievement of complete remission was accompanied by
undetectable anti-THSD7A antibody titers, whereas a major-
ity of those with partial remission and one patient with no
remission remained positive [76]. In contrast to PLA2R1,
THSD7A is expressed on bothmurine and human podocytes,
and administration of human anti-THSD7A antibodies bind
tomurine THSD7A, leading to proteinuria and a histopathol-
ogy resemblingMN [77].This finding confirmed the assump-
tion that antigen-antibody interaction is pivotal in the onset
of MN.
Taken together, anti-THSD7A antibodies are a novel
antigen which is more frequently present in Japanese patients
with primaryMN. In particular, research needs to decipher its
association with malignancy and intensive screening may be
warranted in positive patients, since the number of observed
malignant diseases may be underestimated by the current
reports due to a short follow-up period.
4. Rare Forms of Childhood Membranous
Nephropathy and Potential Ways to the
Detection of Novel Antigens
MN is a common cause of nephrotic syndrome in adults; it is
rare, however in children [78, 79]. Since PLA2R andTHSD7A
do not seem to play any major role in infants and young
children, other auto- or allo-antigens must looked for, after
secondary causes have been excluded thoroughly, particularly
malignancy. Recently, rare causes of MN were identified in
children, such as antibodies to neutral endopetidase (NEP).
A case of antenatalMNwith a severe, unusual histopatho-
logical presentation was further investigated, since the
transplacental passage of nephritogenic antibodies was sus-
pected to be causative. Sequential serum samples from
the mother (before and after delivery) and serum of the
infant after birth showed reactivity with glomerular capillary
walls and the brush border. A 90 kDa antigen was found,
and further experiments identified NEP as the antigenic
fraction. Kidney biopsy of the infant and of rabbits after
incubation with maternal IgG revealed colocalization of IgG
antibodies and NEP in subepithelial immune deposits. The
mother’s granulocytes exhibited a lack of NEP expression,
thus an alloimmunization process was discussed as respon-
sible pathogenetic step [80]. Truncating mutations in the
metallomembrane endopeptidase (MME) gene were found to
be causative of alloimmunization during pregnancy, leading
to the production of anti-NEP antibodies. Whereas infants
of four mothers with mutations had oligoanuria, nephrotic
syndrome or renal failure, all children of one mother had no
overt renal disease. Analysis of anti-NEP antibodies revealed
an approximately 10-fold lower titer for IgG as compared to
those of the remaining mothers. Rapid improvement of kid-
ney failure and nephrotic syndrome was observed in affected
infants [14]. Two mothers were followed during their second
pregnancy. One mother developed a marked increase in
anti-NEP IgG1 and IgG4 antibodies. Severe disease occurred
despite treatment strategies aiming at reducing its levels. The
othermother produced anti-NEP IgG4 antibodies exclusively
and delivery of a healthy newborn was possible [81]. More
recently, two additional mothers (from Germany and Italy)
bearing a truncating deletion in the MME gene were identi-
fied.TheGermanmother produced predominantly anti-NEP
IgG4 antibodies, whereas the Italianmothermainly produced
complement-fixing anti-NEP IgG1 antibodies, the latter able
to inhibit NEP enzymatic activity. Whereas the German
child had rapid regression of all symptoms, the Italian child
required treatment with intermittent peritoneal dialysis and
an impaired renal function at the time of last follow-up was
reported. These findings highlight that complement-fixing
anti-NEP IgG1 antibodies are necessary to develop a severe
disease phenotype [82].
Various reports have already indicated a role for allergens,
including dietary allergens in the pathogenesis of renal
glomerular diseases. Early studies demonstrated that some
patients develop relapses after cow’s milk exposure and
elimination of milk from the diet could prevent relapses of
lipoid nephrosis [83]. This has been explained by a dysregu-
lation of the IL-13 system [84], leading to overproduction of
IgE-specific antibodies of food compounds, including cow’s
milk and theoretically also bovine serum albumin (BSA).
Anti-BSA antibodies, commonly prevalent in the general
population, have been detected in high levels in 4 of 5
consecutive children (age < 5 years) and 7 of 41 consecutive
adults with MN. Elevated levels of circulating BSA were
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also present in those children with high levels of anti-BSA
antibodies. As shown in various animal models, the cationic
form of BSA is able to induce MN. Subepithelial deposits
of BSA were detected in children with both, high levels of
circulating cationic BSA and antibodies, and in the absence
of PLA2R [85].
Gel electrophoresis identified a few proteins which were
repetitively recognized by MN sera. Among these, anti-
bodies against aldose reductase (AR), manganese superox-
ide dismutase (SOD2) were elevated in MN compared to
FGSG and normal controls. Analysis of kidney specimen
revealed marked expression of AR and SOD2 in glomeruli
of patients with MN, and colocalization of both, AR and
SOD2, with IgG4 and the terminal complement complex
[86]. A proteomic approach found three immune proteins in
glomeruli of patients with MN, namely 𝛼-enolase (𝛼ENO),
elongation factor 2 and glycyl aminoacyl-tRNA synthetase.
One of the factors, 𝛼ENO, fulfilled the criteria and was
considered as autoantigen, colocalized with IgG4 in deposits,
and was found to be elevated in 25% of 131 MN patients
[87]. Moreover, PLA2R Ab levels correlated with antibodies
against AR, SOD2 and 𝛼ENO [88]. Recently, Kimura found
no difference in the frequency of 𝛼ENO antibodies between
primary and secondary MN, although IgG4 antibodies were
exclusively found in primary MN [89].
Taken together, rare antigens have been observed in ante-
natal or early-onset membranous nephropathy. In cases with
anti-NEP antibodies, preponderance of IgG4 antibodies was
associated with a good prognosis, whereas a predominance of
IgG1 was accompanied by a severe disease phenotype. More-
over, a role for the cationic formof BSA to causemembranous
nephropathy in children has been described and circulating
antibodies have been observed. Rarer antigens have been
discovered by gel electrophoresis. One can speculate that
more antigens will be discovered in near future.
5. Conclusions and Outlook
The aim of the present review was to summarize recent
literature related to the immunology of primary MN. While
PLA2R-Ab represents the leading circulatory antibody in
primaryMNwith a presence of 70–80%, the role of antibodies
to THSD7A needs to be better defined, since malignancy-
associated THSD7A-related MN has recently been reported
to occur in a significant proportion of patients. Other
antibodies leading to secondary forms of MN have not been
described so far, and there is still room for further antibody
discovery. Moreover, primary MN has a clear genetic basis,
but reports related to genetic heritability are widely lacking.
In addition, novel ELISA kits detecting different epitopes
of PLA2R-Ab may pave the way to distinguish PLA2R-
associatedMN patients with a predictable poor and favorable
outcome. Rare antibodies have been identified in childhood
or antenatal MN. With this increasing research in mind, it is
likely that we will learn more about the etiopathogenesis of
primary and secondary MN in near future.
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